PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 30742941-0 2019 Crizotinib enhances anti-CD30-LDM induced antitumor efficacy in NPM-ALK positive anaplastic large cell lymphoma. Crizotinib 0-10 TNF receptor superfamily member 8 Homo sapiens 25-29 29279550-8 2017 For targeted therapies, an anti-CD30 monoclonal antibody linked to a synthetic antimitotic agent (brentuximab vedotin) and ALK inhibitors (crizotinib, alectinib, and ceritinib) are being used in clinical settings. Crizotinib 139-149 TNF receptor superfamily member 8 Homo sapiens 32-36 30742941-3 2019 In vitro, anti-CD30-LDM showed strong synergistic antiproliferative activity when combined with crizotinib. Crizotinib 96-106 TNF receptor superfamily member 8 Homo sapiens 15-19 30742941-6 2019 Interestingly, the addition of crizotinib inhibited the expression of phosphorylated ERK1/2 and further augmented anti-CD30-LDM-mediated apoptosis, providing a potential synergistic mechanism for DNA-damaging agents combined with NPM-ALK inhibitors. Crizotinib 31-41 TNF receptor superfamily member 8 Homo sapiens 119-123 30742941-8 2019 This research demonstrated for the first time that the combination of anti-CD30-LDM and crizotinib exhibits a synergistic inhibitory effect in tumor cells. Crizotinib 88-98 TNF receptor superfamily member 8 Homo sapiens 75-79